FIBRONEER-ILD Study To Improve Lung Function Request More Information Trial Objective Continuous scarring (fibrosis) can gradually impair lung function, leading to breathing difficulties. Researchers are examining whether an investigational medication called BI 1015550 can help adults aged 18 and older with progressive lung diseases with fibrosis. Participants in this study will be given BI 1015550 or a placebo (a tablet without any medication). All participants receive lung function tests, and the test results for both groups will be compared. Researchers will review the data to see if BI 1015550 improves lung function and may be another important tool in the fight against lung disease. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults 18 and older with progressive interstitial lung disease with fibrosis. Age: 18+ Gender: Any Gender Estimated Time Commitment 10 clinic visits over 52 weeks, then visits every three months until all patients reach 52 weeks of treatment. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Kaitlin Fier 303.270.2852 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Boehringer Ingelheim Principal Investigators Jeff Swigris, DO, MS + × Jeff Swigris, DO, MS Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Continuous scarring (fibrosis) can gradually impair lung function, leading to breathing difficulties. Researchers are examining whether an investigational medication called BI 1015550 can help adults aged 18 and older with progressive lung diseases with fibrosis. Participants in this study will be given BI 1015550 or a placebo (a tablet without any medication). All participants receive lung function tests, and the test results for both groups will be compared. Researchers will review the data to see if BI 1015550 improves lung function and may be another important tool in the fight against lung disease.